• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

非小细胞肺癌中的驱动突变免疫微环境:通过聚类分析揭示模式。

Mutation-Driven Immune Microenvironments in Non-Small Cell Lung Cancer: Unrevealing Patterns through Cluster Analysis.

机构信息

Department of Research Support, Yonsei Biomedical Research Institute, Yonsei University College of Medicine, Seoul, Korea.

Severance Biomedical Science Institute, Yonsei University College of Medicine, Seoul, Korea.

出版信息

Yonsei Med J. 2024 Dec;65(12):683-694. doi: 10.3349/ymj.2024.0062.

DOI:10.3349/ymj.2024.0062
PMID:39609084
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11605048/
Abstract

PURPOSE

We aimed to comprehensively analyze the immune cell and stromal components of tumor microenvironment at the single-cell level and identify tumor heterogeneity among the major top-derived oncogene mutations in non-small cell lung cancer (NSCLC) using single-cell RNA sequencing (scRNA-seq) data.

MATERIALS AND METHODS

The scRNA-seq dataset utilized in this study comprised 64369 primary tumor tissue cells from 21 NSCLC patients, focusing on mutations in , , , , , and the wild-type.

RESULTS

Tumor immune microenvironment (TIM) analysis revealed differential immune responses across NSCLC mutation subtypes. TIM analysis revealed different immune responses across the mutation subtypes. Two mutation clusters emerged: , , and + mutations (MC1); and , , and mutations (MC2). MC1 showed higher tertiary lymphoid structures signature scores and enriched populations of C2-T-IL7R, C3-T/NK-CXCL4, C9-T/NK-NKG, and C1-B-MS4A1 clusters than cluster 2. Conversely, MC2 cells exhibited higher expression levels of , , and chemokines linked to alternative immune pathways. Remarkably, co-occurring and mutations were grouped as MC1. + mutations showed upregulation of peptide synthesis and higher synthetic processes, as well as differences in myeloid and T/NK cells compared to mutations. In T/NK cells, + mutations showed a higher expression of features related to cell activity and differentiation, whereas mutations showed the opposite.

CONCLUSION

Our research indicates a close association between mutation types and tumor microenvironment in NSCLC, offering insights into personalized approaches for cancer diagnosis and treatment.

摘要

目的

我们旨在通过单细胞 RNA 测序 (scRNA-seq) 数据,在单细胞水平上全面分析肿瘤微环境中的免疫细胞和基质成分,并识别非小细胞肺癌 (NSCLC) 主要致癌基因突变中的肿瘤异质性。

材料和方法

本研究使用的 scRNA-seq 数据集包含 21 名 NSCLC 患者的 64369 个原发性肿瘤组织细胞,重点关注 、 、 、 、 和野生型中的突变。

结果

肿瘤免疫微环境 (TIM) 分析显示 NSCLC 突变亚型之间存在不同的免疫反应。TIM 分析显示突变亚型之间存在不同的免疫反应。出现了两个突变簇: 、 、 + 突变 (MC1); 和 、 、 突变 (MC2)。MC1 表现出更高的三级淋巴结构特征评分,以及更丰富的 C2-T-IL7R、C3-T/NK-CXCL4、C9-T/NK-NKG 和 C1-B-MS4A1 簇群体,而簇 2 则没有。相反,MC2 细胞表现出更高的 、 、 和与替代免疫途径相关的趋化因子的表达水平。值得注意的是,共同发生的 和 突变被归类为 MC1。+ 突变表现出肽合成和更高的合成过程上调,以及与 突变相比髓样细胞和 T/NK 细胞的差异。在 T/NK 细胞中,+ 突变表现出与细胞活性和分化相关的特征表达上调,而 突变则表现出相反的情况。

结论

我们的研究表明 NSCLC 中突变类型与肿瘤微环境之间存在密切关联,为癌症诊断和治疗的个性化方法提供了新的见解。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6c40/11605048/513ab85d9364/ymj-65-683-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6c40/11605048/0221a4b1fa2f/ymj-65-683-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6c40/11605048/3d7e586d4cf4/ymj-65-683-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6c40/11605048/01573746ffbb/ymj-65-683-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6c40/11605048/2418ebf224b9/ymj-65-683-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6c40/11605048/513ab85d9364/ymj-65-683-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6c40/11605048/0221a4b1fa2f/ymj-65-683-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6c40/11605048/3d7e586d4cf4/ymj-65-683-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6c40/11605048/01573746ffbb/ymj-65-683-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6c40/11605048/2418ebf224b9/ymj-65-683-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6c40/11605048/513ab85d9364/ymj-65-683-g005.jpg

相似文献

1
Mutation-Driven Immune Microenvironments in Non-Small Cell Lung Cancer: Unrevealing Patterns through Cluster Analysis.非小细胞肺癌中的驱动突变免疫微环境:通过聚类分析揭示模式。
Yonsei Med J. 2024 Dec;65(12):683-694. doi: 10.3349/ymj.2024.0062.
2
Clinical features and therapeutic options in non-small cell lung cancer patients with concomitant mutations of EGFR, ALK, ROS1, KRAS or BRAF.非小细胞肺癌患者同时存在 EGFR、ALK、ROS1、KRAS 或 BRAF 突变的临床特征和治疗选择。
Cancer Med. 2019 Jun;8(6):2858-2866. doi: 10.1002/cam4.2183. Epub 2019 Apr 24.
3
Correlation between Programmed Death Ligand-1(PD-L1) Expression and Driver Gene Mutations in Non-Small Cell Lung Carcinoma- Adenocarcinoma Phenotype.程序性死亡配体-1(PD-L1)表达与非小细胞肺癌-腺癌表型中驱动基因突变的相关性。
Asian Pac J Cancer Prev. 2022 Jan 1;23(1):131-142. doi: 10.31557/APJCP.2022.23.1.131.
4
Molecular heterogeneity of anti-PD-1/PD-L1 immunotherapy efficacy is correlated with tumor immune microenvironment in East Asian patients with non-small cell lung cancer.抗 PD-1/PD-L1 免疫疗法疗效的分子异质性与东亚非小细胞肺癌患者的肿瘤免疫微环境相关。
Cancer Biol Med. 2020 Aug 15;17(3):768-781. doi: 10.20892/j.issn.2095-3941.2020.0121.
5
Characteristics of the immune microenvironment and their clinical significance in non-small cell lung cancer patients with ALK-rearranged mutation.具有 ALK 重排突变的非小细胞肺癌患者的免疫微环境特征及其临床意义。
Front Immunol. 2022 Sep 8;13:974581. doi: 10.3389/fimmu.2022.974581. eCollection 2022.
6
Integration of comprehensive genomic profiling, tumor mutational burden, and PD-L1 expression to identify novel biomarkers of immunotherapy in non-small cell lung cancer.综合基因组分析、肿瘤突变负担和 PD-L1 表达的整合,以鉴定非小细胞肺癌免疫治疗的新型生物标志物。
Cancer Med. 2021 Apr;10(7):2216-2231. doi: 10.1002/cam4.3649. Epub 2021 Mar 2.
7
Actionable Mutation Profiles of Non-Small Cell Lung Cancer patients from Vietnamese population.越南人群非小细胞肺癌患者的可操作突变特征。
Sci Rep. 2020 Feb 17;10(1):2707. doi: 10.1038/s41598-020-59744-3.
8
The prognostic effect of single and multiple cancer-related somatic mutations in resected non-small-cell lung cancer.切除的非小细胞肺癌中单种和多种癌症相关体细胞突变的预后影响。
Lung Cancer. 2018 Sep;123:22-29. doi: 10.1016/j.lungcan.2018.06.023. Epub 2018 Jun 19.
9
Prognostic value of TP53 concurrent mutations for EGFR- TKIs and ALK-TKIs based targeted therapy in advanced non-small cell lung cancer: a meta-analysis.TP53 并发突变对晚期非小细胞肺癌 EGFR-TKIs 和 ALK-TKIs 靶向治疗的预后价值:一项荟萃分析。
BMC Cancer. 2020 Apr 16;20(1):328. doi: 10.1186/s12885-020-06805-5.
10
ROS1 Fusions Rarely Overlap with Other Oncogenic Drivers in Non-Small Cell Lung Cancer.ROS1融合在非小细胞肺癌中很少与其他致癌驱动因素重叠。
J Thorac Oncol. 2017 May;12(5):872-877. doi: 10.1016/j.jtho.2017.01.004. Epub 2017 Jan 11.

本文引用的文献

1
CZ CELLxGENE Discover: a single-cell data platform for scalable exploration, analysis and modeling of aggregated data.CZ CELLxGENE发现平台:一个用于对聚合数据进行可扩展探索、分析和建模的单细胞数据平台。
Nucleic Acids Res. 2025 Jan 6;53(D1):D886-D900. doi: 10.1093/nar/gkae1142.
2
Efficacy and safety analysis of immune checkpoint inhibitor rechallenge therapy in locally advanced and advanced non-small cell lung cancer: a retrospective study.免疫检查点抑制剂再挑战疗法在局部晚期和晚期非小细胞肺癌中的疗效与安全性分析:一项回顾性研究
J Thorac Dis. 2024 Mar 29;16(3):1787-1803. doi: 10.21037/jtd-23-1767. Epub 2024 Mar 19.
3
Roles of tissue-resident immune cells in immunotherapy of non-small cell lung cancer.
组织驻留免疫细胞在非小细胞肺癌免疫治疗中的作用。
Front Immunol. 2023 Dec 7;14:1332814. doi: 10.3389/fimmu.2023.1332814. eCollection 2023.
4
Comparison of the somatic genomic landscape between central- and peripheral-type non-small cell lung cancer.中枢型与周围型非小细胞肺癌体细胞基因组图谱的比较。
Lung Cancer. 2024 Jan;187:107439. doi: 10.1016/j.lungcan.2023.107439. Epub 2023 Dec 12.
5
Recent advances in non-small cell lung cancer targeted therapy; an update review.非小细胞肺癌靶向治疗的最新进展;综述更新
Cancer Cell Int. 2023 Aug 11;23(1):162. doi: 10.1186/s12935-023-02990-y.
6
The global burden of lung cancer: current status and future trends.全球肺癌负担:现状与未来趋势。
Nat Rev Clin Oncol. 2023 Sep;20(9):624-639. doi: 10.1038/s41571-023-00798-3. Epub 2023 Jul 21.
7
Immunotherapy resistance in non-small-cell lung cancer: From mechanism to clinical strategies.非小细胞肺癌的免疫治疗抵抗:从机制到临床策略。
Front Immunol. 2023 Apr 6;14:1129465. doi: 10.3389/fimmu.2023.1129465. eCollection 2023.
8
Targeted therapies for KRAS-mutant non-small cell lung cancer: from preclinical studies to clinical development-a narrative review.KRAS 突变型非小细胞肺癌的靶向治疗:从临床前研究到临床开发——一篇叙述性综述
Transl Lung Cancer Res. 2023 Feb 28;12(2):346-368. doi: 10.21037/tlcr-22-639. Epub 2023 Feb 20.
9
Single-Cell Analysis Reveals Transcriptomic Features of Drug-Tolerant Persisters and Stromal Adaptation in a Patient-Derived EGFR-Mutated Lung Adenocarcinoma Xenograft Model.单细胞分析揭示了患者来源的表皮生长因子受体(EGFR)突变型肺腺癌异种移植模型中耐药持久性细胞的转录组特征和基质适应性。
J Thorac Oncol. 2023 Apr;18(4):499-515. doi: 10.1016/j.jtho.2022.12.003. Epub 2022 Dec 16.
10
High-resolution single-cell atlas reveals diversity and plasticity of tissue-resident neutrophils in non-small cell lung cancer.高分辨率单细胞图谱揭示了非小细胞肺癌中组织驻留中性粒细胞的多样性和可塑性。
Cancer Cell. 2022 Dec 12;40(12):1503-1520.e8. doi: 10.1016/j.ccell.2022.10.008. Epub 2022 Nov 10.